Busines Wire - May 3, 2000
In January, Vice President Al Gore told a National Security Council session on AIDS that the disease had become "a security threat of the greatest magnitude."
"Our hope for the future is that the administration significantly increases funding for prevention as well as for curative medicine," stated Dr. Janet Greeson, executive vice president. "STGI continues its role as a company founded with the intent of developing affordable therapeutic drugs to impact the lives of ones inflicted with HIV."
The interview in its entirety can be found at http://64.35.24.87/reallyreal/stgiaid.ram. Additionally, Greeson addressed in the interview the two latest press releases concerning ANTICORT(tm) patents and investment banking opportunities.
Furthermore, Greeson stated, "There are two compelling things about our drug: One, we hope that our clinical research will find ANTICORT(tm) to have minimal side effects and two, that the inexpensive cost of our drug will make ANTICORT(tm) available to every person afflicted with AIDS or HIV, regardless of their financial status. Steroidogenesis Inhibitors International is ready to advance into the next stage of our growth, which is why we have set out to explore investment banking and patent opportunities."
STGI is a pharmaceutical company with its core technology being ANTICORT(tm), which is currently in clinical and non-clinical trials as an anticortisol, steroidogenesis inhibitor drug for the treatment of immune deficiency in AIDS/HIV positives.
This release contains statements about the future that could differ from actual results. The statements are subject to risk and uncertainties, including, but not limited to, the impact of competition, fluctuations in stock price and liquidity, fluctuating operating results and other risks.
CONTACT: STGI Janet Greeson, Ph.D., 702/222-1988 or Performance Strategies, Inc. Richard L. Brown or Chuck Jordan, 303/948-3601
000503
BW000501
Copyright © 2000 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .